Christopher James Frankenfield, CFO of Xilio Therapeutics ($XLO), made one open market sale of company shares in the last year, totaling about $4,522. His most recent sale occurred on January 2, 2026. These sales rank 11,419th among 11,678 insiders in our database, where the average is $8.6 million across about 6.4 transactions. He had no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 1, 2026 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | M | Common Stock | 19375 | $0.00 | 31,796.0000 | 144,106,869 | 155.99% | 0.01% |
| Jan. 1, 2026 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | M | Restricted Stock Units | 19375 | $0.00 | 38,750.0000 | 144,106,869 | 33.33% | 0.01% |
| Dec. 31, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | A | Stock Option (right to buy) | 668789 | $0.00 | 668,789.0000 | 144,106,869 | 9999.99% | 0.46% |
| Jan. 2, 2026 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | S | Common Stock | 7030 | $0.64 | 24,766.0000 | 144,106,869 | 22.11% | 0.00% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | A | Stock Option (right to buy) | 37296 | $0.00 | 37,296.0000 | 144,106,869 | 9999.99% | 0.03% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | D | Stock Option (right to buy) | 20000 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.01% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | A | Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 144,106,869 | 9999.99% | 0.01% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | D | Stock Option (right to buy) | 117000 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.08% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | A | Stock Option (right to buy) | 117000 | $0.00 | 117,000.0000 | 144,106,869 | 9999.99% | 0.08% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | D | Stock Option (right to buy) | 150000 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.10% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | A | Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 144,106,869 | 9999.99% | 0.10% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | D | Stock Option (right to buy) | 300000 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.21% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | A | Stock Option (right to buy) | 300000 | $0.00 | 300,000.0000 | 144,106,869 | 9999.99% | 0.21% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | A | Stock Option (right to buy) | 925000 | $0.00 | 925,000.0000 | 144,106,869 | 9999.99% | 0.64% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | D | Stock Option (right to buy) | 155090 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.11% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | A | Stock Option (right to buy) | 155090 | $0.00 | 155,090.0000 | 144,106,869 | 50.00% | 0.11% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | D | Stock Option (right to buy) | 23786 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.02% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | A | Stock Option (right to buy) | 23786 | $0.00 | 23,786.0000 | 144,106,869 | 9999.99% | 0.02% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | D | Stock Option (right to buy) | 37296 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.03% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | D | Stock Option (right to buy) | 45000 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.03% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | A | Stock Option (right to buy) | 45000 | $0.00 | 45,000.0000 | 144,106,869 | 9999.99% | 0.03% |
| April 15, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | A | Stock Option (right to buy) | 75000 | $0.00 | 75,000.0000 | 63,465,063 | 9999.99% | 0.12% |
| Jan. 1, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | A | Stock Option (right to buy) | 251000 | $0.00 | 251,000.0000 | 63,465,063 | 9999.99% | 0.40% |
| Jan. 1, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | M | Restricted Stock Units | 19375 | $0.00 | 58,125.0000 | 63,465,063 | 25.00% | 0.03% |
| Jan. 2, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | S | Common stock | 6954 | $0.98 | 12,421.0000 | 63,465,063 | 35.89% | 0.01% |
| Jan. 1, 2025 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Financial Officer | M | Common Stock | 19375 | $0.00 | 19,375.0000 | 63,465,063 | 9999.99% | 0.03% |
| Aug. 3, 2024 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | Chief Operating Officer | A | Stock Option (right to buy) | 52000 | $0.00 | 52,000.0000 | 0 | 9999.99% | 0.00% |
| May 1, 2024 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | CHIEF OPERATING OFFICER | A | Stock Option (right to buy) | 208000 | $0.00 | 208,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 1, 2024 | Xilio Therapeutics, Inc. | $XLO | Frankenfield Christopher James | CHIEF OPERATING OFFICER | A | Restricted Stock Units | 77500 | $0.00 | 77,500.0000 | 0 | 9999.99% | 0.00% |